At Axis-Shield, innovation is fundamental to our business.

Our expertise encompasses the development of novel proprietary diagnostic tests in areas of clinical need and their incorporation onto the menus of the high throughput analysers of our partners, using a variety of assay technologies.

We specialise in unique markers for the early diagnosis and management of critical illnesses:

  • Cardiovascular and neurodegenerative diseases
  • Rheumatoid Arthritis
  • Sepsis
  • Vitamin deficiencies
  • Diabetes

Our proprietary tests and technologies to measure HbA1c, Homocysteine, anti-CCP (for early detection of rheumatoid arthritis) and Active-B12 (for better detection of vitamin B12 deficiency) are driving revenues and there has also been much interest in our newer markers such as Heparin Binding Protein for diagnosis and prediction of severe sepsis.

There is an increasing need for new diagnostic tests in many disease areas, including those associated with an increasingly ageing population. Identifying these diseases quickly and efficiently can be vital in maintaining a patient’s quality of life. New drug modalities are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy.

The core focus of our business continues to be on innovation and the development of new markers that will increase testing and improve patient care.

Since our inception, we have successfully implemented our strategy of growth through the development and marketing of novel diagnostic tests in areas of clinical need.

We welcome discussion with organisations or individuals wishing to accelerate development, clinical evaluation and commercialisation of any novel markers with potential clinical utility.

Please contact us for more information.